GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genesystem Co Ltd (XKRX:363250) » Definitions » Debt-to-Asset

Genesystem Co (XKRX:363250) Debt-to-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Genesystem Co Debt-to-Asset?

Genesystem Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩0.0 Mil. Genesystem Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩0.0 Mil. Genesystem Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ₩36,583.1 Mil. Genesystem Co's debt to asset for the quarter that ended in Mar. 2024 was 0.00.


Genesystem Co Debt-to-Asset Historical Data

The historical data trend for Genesystem Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genesystem Co Debt-to-Asset Chart

Genesystem Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
0.28 0.21 0.08 0.10 0.12

Genesystem Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.11 0.12 0.12 -

Competitive Comparison of Genesystem Co's Debt-to-Asset

For the Diagnostics & Research subindustry, Genesystem Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genesystem Co's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genesystem Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Genesystem Co's Debt-to-Asset falls into.



Genesystem Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Genesystem Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1380.502 + 3107.177) / 38927.991
=0.12

Genesystem Co's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genesystem Co  (XKRX:363250) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Genesystem Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Genesystem Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Genesystem Co (XKRX:363250) Business Description

Traded in Other Exchanges
N/A
Address
200-9, Techno 2-ro, Yuseong-gu, Daejeon, KOR, 34028
Genesystem Co Ltd is a biotech engineering company specializing in molecular testing solutions that target on-site testing needs. It develops and markets state-of-the-art PCR platforms as well as related reagents and biochip products designed to enhance the health of human societies and improve the quality of human life.

Genesystem Co (XKRX:363250) Headlines

No Headlines